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A central issue in the study of autoimmunity con-
cerns the nature of the autologous peptides rec-
ognized by the autoreactive T cells: do certain 
self peptides bound to MHC molecules have dis-
tinctive features that allow for the activation of 
autoreactive T cells? Issues of binding affinity,   
posttranslational modifications, conformational 
isomers,  and  register  shifting  of  self  peptides 
have all been the subject of analysis by many 
laboratories (Liu et al., 1995; Anderton, 2004; 
Bankovich et al., 2004; Lovitch and Unanue, 
2005; Goverman, 2009). Solutions to these vari-
ous issues could potentially explain why self-
reactive T cells escape thymic selection and 
subsequently become pathogenic in the target 
tissue. Our own interest centers on whether the 
peptide–MHC (pMHC) complex presented by 
tissue APCs may be distinct compared with 
the pMHC being presented, if at all, by thymic 
APCs during T cell selection.
In the nonobese diabetic (NOD) mouse, the 
islet  autoimmune  response  is  highly  focused 
against the insulin molecule. The insulin autore-
activity is a major contributing factor and is es-
sential for the development of diabetes (Daniel   
et al., 1995; French et al., 1997; Jaeckel et al.,   
2004; Nakayama et al., 2005, 2007). A recent 
study of ours analyzing the T cell response 
during diabetogenesis of NOD mice led to the 
identification  of  a  notable  set  of  autoreactive 
CD4+ T cells that recognized insulin peptides 
found in the early islet infiltrates of NOD mice 
(Mohan et al., 2010). These CD4+ T cells recog-
nized the 9–23 residue stretch of the insulin B 
chain (B:9–23), a peptide which binds to I-Ag7 at 
very low affinity with a fast rate of dissociation 
(Yu et al., 2000; Levisetti et al., 2007). Impor-
tantly, most of the anti-insulin T cells did not rec-
ognize the B:9–23 segment when the insulin 
protein was processed by the APCs; these T cells 
only recognized the B:9–23 segment when it was 
offered as an exogenous peptide. In brief, we iden-
tified subsets of T cells against an insulin epitope 
that exhibited a pattern of reactivity akin to 
T cells identified when studying the protein hen 
egg white lysozyme (HEL), which we had termed 
type A and B (Lovitch and Unanue, 2005).
These insulin peptide–specific T cells were 
readily activated by APCs normally inhabiting 
the islets of Langerhans (Calderon et al., 2008) 
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In nonobese diabetic (NOD) mice, two sets of autoreactive CD4+ T cells recognize the B:9–
23 segment of the insulin B chain. One set, type A, recognizes insulin presented by antigen-
presenting cells (APCs). These T cells are highly deleted in the thymus. The second set,  
type B, does not recognize insulin protein but reacts with soluble B chain peptide. This set 
is not deleted in the thymus but is activated in the islets of Langerhans. In this study, we 
examine the specificity of these two types of T cells. The protein-reactive set recognizes 
the stretch of residues 13–21 of the insulin B chain. The set reactive to peptide only 
recognizes the stretch from residues 12–20. A single amino acid shift of the B chain pep-
tide bound to I-Ag7 determines whether T cells recognize peptides generated by the pro-
cessing of insulin, and consequently their escape from thymic purging. Biochemical experiments 
indicate that peptides bound in the 13–21 register interact more favorably with I-Ag7 than 
peptides that bind in the 12–20 register. Thus, self-reactive T cells can become pathogenic 
in the target organ where high concentrations of antigen and/or differences in intracellular 
processing present peptides in registers distinct from those found in the thymus.
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Noncommercial–Share Alike–No Mirror Sites license for the first six months after the 
publication date (see http://www.rupress.org/terms). After six months it is available 
under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Un-
ported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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NOD mice or by immunization with the insulin B chain 
peptide encompassing residues 9–23. These B:9–23-reactive 
T cell hybridomas were divided into two groups based on 
their ability to recognize the insulin protein processed by 
APCs in standard T cell assays. Those that recognized both 
insulin and B:9–23 peptide presented by APCs were called 
type A T cells, whereas those only recognizing the B:9–23 
peptide but not the insulin molecule were called type B   
(Mohan et al., 2010). In this study, the ability of these T cells 
to recognize mouse preproinsulin proteins was tested in two 
experimental systems: in one, the C3.G7 APC line was cul-
tured with recombinant mouse preproinsulin I or II, and in 
the other manipulation, the same APC was engineered to 
endogenously express mouse preproinsulin I or II via retroviral 
transduction of their respective cDNA.
Both type A and B T cells were activated by adding the 
B:9–23 peptide to the C3.G7 APC line (Fig. 1 a). The type A 
T cells recognized recombinant mouse preproinsulin I and II 
when added to the APC (Fig. 1 a) or to either of the proteins 
expressed in the C3.G7 line (Fig. 1 b). Type B T cells were 
incapable  of  recognizing  preproinsulin  in  either  situation 
(Fig. 1, a and b). Collectively, these results confirmed our pre-
vious findings using exogenous human insulin (Mohan et al., 
2010): the type B T cells did not recognize the B:9–23 epi-
tope generated by the processing of mouse insulin proteins.
A previous study in the laboratory indicated that T cells 
reacted only to two partially overlapping nine amino acid 
but not by any other tissue APCs, including those in the thymus. 
Importantly, the secretory granules from  cells, in addition to 
containing the high amounts of mature insulin molecules, also 
contained peptide fragments derived from the insulin protein. 
These granules were taken up by the intraislet APCs and 
charged their MHC molecules with insulin-derived peptides, 
explaining the activation of these peptide-specific T cells. Such 
peptide-specific T cell lines transferred into nondiabetic NOD 
mice were specifically recruited to the islets and caused diabetes 
(Mohan et al., 2010). The fact that these peptide-specific T cells 
are not clonally deleted in the thymus, even though they are 
pathogenic, unmistakably underscores their importance.
In this study, we examine and explain the features of the 
CD4+ type A and B T cells against the B chain of insulin. The 
explanation for their dissimilar reactivity lies in the peptide seg-
ment being recognized: type A T cells recognized the B:13–21 
register bound to I-Ag7, whereas type B T cells recognized the 
B:12–20 register. A single residue shift of the peptide segment 
bound within the binding groove of the MHC distinguished 
both sets of autoreactive T cells. An explanation for such dis-
tinction lies in the binding properties of each segment.
RESULTS AND DISCUSSION
Insulin-reactive type A and B T cells recognize different 
registers of the B:9–23 peptide
Previously, a cohort of insulin-reactive CD4+ T cell hybrid-
omas was generated from the infiltrated islets of prediabetic 
Figure 1.  Type A and B reactive T cells recognize distinct registers of the B:9–23 peptide. (a) IL-2 production by T cell hybridomas in response to 
B:9–23 peptide, mouse preproinsulin I, or mouse preproinsulin II, presented by the C3.G7 APC cell line. (b) IL-2 production in response to C3.G7 cells ex-
pressing mouse preproinsulin I and preproinsulin II cDNA constructs. (c and d) Response of two type A hybridomas (4F7 and IIT-3; c) and two type B hy-
bridomas (8F10 and 2D10; d) to the B:12–20 (register 1) and B:13–21 (register 2) peptides covalently linked to I-Ag7 expressed on C3.G7 cells. (e) Response 
of type A and type B hybridomas to the B:14–23 peptide linked to I-Ag7 (register 3) expressed on M12.C3 cells. Error bars indicate SEM. Data are represen-
tative of three independent experiments.JEM Vol. 208, No. 12  2377
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recognized by type A T cells but not by type B T cells (Fig. 2 a). 
Thus, regardless of the N-terminal flank length, the covalently 
bound peptide was always presented in register 2:13–21.
Next,  covalent  complexes  with  truncations  of  the   
C-terminal residues were examined. A cell line with truncation 
of two amino acids at the C terminus of the peptide (C3.
G7B:9–21) was only recognized by type A T cells and not by 
type B T cells (Fig. 2 b). Pointedly, when the C terminus was 
further truncated by removing the B21 glutamic acid to gen-
erate the C3.G7B:9–20 cell line, the opposite outcome was 
observed. The G7B:9–20 complex was recognized by type B 
T cells but not by the type A T cells (Fig. 2 b).
These results suggest that the glutamic acid at position   
21 in the covalently linked pMHC locks register 2 in the 
peptide-containing groove of I-Ag7 molecules; register 1 is 
only presented when this residue is absent in the covalently 
linked complexes. Therefore, we surmised that the addition 
of a single amino acid, the B21 glutamic acid, to the B:12–20 
peptide should shift the presentation from register 1:12–20 to 
register 2:13–21. Accordingly, a covalent cell line expressing 
B:12–21  (VEALYLVCGE),  which  contains  the  minimal 
peptide encompassing the two registers, was only recognized 
by type A T cells and not by type B T cells (Fig. 2 c).
registers within the B:9–23 peptide, (SHLVEALYLVCGERG; 
Levisetti et al., 2007): register 1 encompassing the 12–20 
(VEALYLVCG)  segment  and  register  2  using  the  13–21 
(EALYLVCGE) segment (the P9 residue of each is under-
lined). To test whether type A or B T cells were restricted to 
one of the two registers of the peptide bound to the I-Ag7 
MHC molecule, APCs were generated containing the mini-
mal registers covalently bound to the I-Ag7  chain via a flex-
ible glycine/serine linker (Kozono et al., 1994; Landais et al., 
2009). These constructs, along with the I-Ag7  chain were 
expressed in the M12.C3 B lymphoma cell line. All cell lines 
used  in  these  experiments  expressed  comparable  levels  of   
I-Ag7 on the cell surface (not depicted).
Constructs containing either register 1 or register 2 seg-
ments covalently bound to the I-Ag7  chain were generated 
and expressed in the M12.C3 cell line. The cell line express-
ing the register 2:13–21 segment covalently linked to I-Ag7 
(C3.G7B:13–21) was exclusively recognized by the type A   
T cells but not by the type B T cells (Fig. 1, c and d). We 
found no examples of a type B T cell activated by the register 
2:13–21 complex. In striking contrast, the type B T cells rec-
ognized the register 1:12–20 segment covalently linked to   
I-Ag7 (C3.G7B:12–20; Fig. 1, c and d). Whereas the majority 
of type A T cells only recognized the C3.G7B:13–21 cell 
line, interestingly, a subset of them also recognized register 
1:12–20 covalently linked to I-Ag7 (Fig. 1 c).
A third potential binding register previously suggested to 
encompass the B:14–22 segment (register 3:14–22) of the pep-
tide (Stadinski et al., 2010) was evaluated. A cell line expressing 
the B:14–23 segment covalently linked to I-Ag7 (C3.G7B: 
14–23) did not stimulate any type A or B hybridomas (Fig. 1 e).
Although no type B T cells recognized register 2, a subset 
of type A T cells recognized both registers 1 and 2 covalently 
bound; note in Table S1 their incidence to presentation by C3.
G7B:12–20 and to C3.G7B:9–20. Further studies are needed to 
examine their specificity; such a group may recognize the 13–20 
segment plus the adjacent glycine from the linker of the cova-
lent constructs (i.e. EALYLVCGG; putative P9 underlined) or 
may recognize the 12–20 segment in a cross-reactive way. The 
recognition of the 12–20 segment by type A T cells in general 
was considerably weaker than the 13–21 segment, and the best 
example is that of the T cell shown (Fig. 2 a). Moreover, as sum-
marized in Table S2, many of these dual reactive T cells did not 
recognize a soluble peptide containing the register 1:12–20, 
which is another indication of their weak cross-reactivity.
The B21 glutamic acid influences register selection  
of covalent pMHC
In our previous study (Mohan et al., 2010), only the type A 
T cells but not the type B T cells recognized the covalent 
linkage of the entire B:9–23 peptide to I-Ag7. This indicated 
that the linked B:9–23 peptide was solely bound in register 
2:13–21. To address this issue, a panel of truncated B:9–23 
peptides covalently linked to the I-Ag7 molecule was devel-
oped to determine which residues influenced register binding. 
Peptides with various lengths of the N-terminal flank were all 
Figure 2.  The glutamic acid at B21 determines register binding of 
covalently linked insulin pMHC molecules. (a) Response of type A (IIT-3) 
and type B (8F10) hybridomas to N-terminal truncated variants of the 
B:9–23 peptide covalently linked to I-Ag7 expressed on M12.C3 cells.  
(b) Type A (IIT-3) and type B (8F10) T cell response to cells expressing co-
valently linked B:9–20 and B:9–21 C-terminal truncations of B:9–23.  
(c) Type A (IIT-3) and type B (8F10) T cell response to the G7B:12–21 cell 
line. Error bars indicate SEM. Data are representative of three indepen-
dent experiments.2378 Register shift dictates diabetogenic T cell fate | Mohan et al.
peptides lacking this residue were presented in register 1. 
Without the constraints imposed by the intracellular handling 
of insulin by APCs (or by the use of covalent linkages), solu-
ble peptides have the flexibility to be presented in both regis-
ter 1 and register 2. These findings, summarized in Tables S1 
and S2, indicate that register 2 was highly favored under 
physiological conditions such as when insulin was processed 
and presented by the APCs.
Immunization elicits register 1–reactive type B  
T cells in vivo
NOD mice were unresponsive to immunization with insulin 
protein  but  responded  to  immunization  with  the  B:9–23 
peptide, generating T cells that exhibited type B reactivity, 
only responding to the peptide but not to insulin (Mohan   
et al., 2010). Linking these previous findings to the aforemen-
tioned results, the expectation would be that the majority   
of B:9–23 T cells elicited in NOD mice would recognize 
register 1:12–20. Conversely, immunization with a register 
2:13–21 peptide should not elicit a response: mice are highly 
tolerant to insulin, and insulin processing by APCs mainly gen-
erated register 2:13–21. These expectations were fulfilled.
NOD mice immunized with the B:9–23 or nested regis-
ter 1 peptide emulsified in CFA elicited a strong ELISPOT 
response to the B:9–23 peptide and also to the nested register 1 
peptide but not to the nested register 2 peptide or insulin 
(Fig. 4 a). The response was inhibited with the addition of 
anti–I-Ag7 antibody in the assay. Mice that were immunized 
with insulin protein or the nested register 2 peptide did not 
elicit a response to any of the peptides (Fig. 4 b).
In our previous study, we showed that type A T cells es-
caped thymic selection and could be elicited after immuniza-
tion of the insulin mutant strain B16:A-dKO (Mohan et al., 
2010). These mice have targeted dele-
tions  of  the  native  INS1  and  INS2 
genes  but  express  a  mutant  insulin 
molecule that has a single amino acid 
substitution (tyrosine to alanine) at the 
16th residue of the B chain (Nakayama 
et al., 2005). When B16A-dKO mice 
were immunized with the B:9–23 pep-
tide, we detected a response to register 1 
similar to that found in NOD mice, 
Synthetic peptides confirm register reactivity  
of A and B T cells
The findings with covalently bound peptides were extended 
using soluble peptides. Although both sets of T cells recog-
nized the B:9–23 peptide, the type A or B T cells did not rec-
ognize the B:12–20 or B:13–21 minimal register peptides 
when presented by APCs (Fig. 3 a). These findings confirm 
that the residues flanking the minimal binding core are re-
quired for recognition by insulin-reactive T cells (Levisetti   
et al., 2007). To circumvent this issue, synthetic peptides were 
designed containing a single register (underlined in the fol-
lowing sequences) nested between artificial flanking residues. 
The three amino and carboxyl flanking residues present in 
the covalently linked insulin-pMHC molecules were added 
to the peptides containing the core registers (Table S2). Akin 
to the covalently linked cell lines, type B T cells only recog-
nized the soluble peptide containing the nested register 1, 
with flanking residues (TEGVEALYLVCGGGS; Fig. 3 b). 
Conversely, a similar peptide containing the nested register 2 
(TEGEALYLVCGEGGS) was recognized by type A T cells 
but not by type B T cells (Fig. 3 b). Similar to the natural 
B:9–23 peptide, peptides containing both registers as their 
core,  B:12–21  (GTEVEALYLVCGEGGS)  and  B:12–22 
(TEGVEALYLVCGERGGS), were recognized by both type A 
and B T cells (Fig. 3 c). A peptide containing register 3, 
B:14–22, nested with the same flanks (TEGALYLVCGERGGS) 
was not recognized by any of the T cells (Fig. 3 d).
In summary, type A T cells specifically recognized regis-
ter 2:13–21, whereas type B T cells specifically recognized 
register 1:12–20. The P9 glutamic acid (B21) of register 2 
had a seminal role in register selection of covalently bound 
peptides. All covalently linked peptides containing the B21 
glutamic acid were presented on I-Ag7 in register 2, whereas 
Figure 3.  Type A and B T cells recognize 
independent registers within the B:9–23 
soluble peptide. (a) Response of type A (4F7 
and 4E4-62) and type B (8F10 and 2D10) 
hybridomas to B:9–23, B:12–20, or B:13–21.  
(b) Response to nested B:12–20 with flanking 
residues or nested B:13–21 with flanking 
residues. (c) Response to nested B:12–21 with 
flanking residues or nested B:12–22 with 
flanking residues. (d) Response to nested 
B:14–22 with flanking residues. Error bars 
indicate SEM. Data are representative of three 
independent experiments.JEM Vol. 208, No. 12  2379
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Biochemical features of the two main binding segments
The same nested peptides containing the flanking residues 
and the core segments (Table S2) were tested in binding   
assays to purified I-Ag7 molecules. Peptides containing register 
2:13–21 bound better than those containing register 1:12–20, 
0.7 µM versus 1.4 µM, respectively. The nested 12–20 regis-
ter peptide required about double the amount of free peptide 
to inhibit the binding of a standard radioactive peptide in 
contrast to that of the nested 13–21 register (Table S2; in 
seven different experiments with P < 0.03). The peptide 
having the 12–21 segment, i.e., both registers, bound at about 
the same strength, 0.5 µM, to that of register 2:13–21. Chang-
ing the P9 residue to a lysine of register 2:13–21 peptide 
greatly decreased the binding capacity and completely inhib-
ited T cell reactivity (Fig. 5 a and Table S2), confirming the 
binding register. The effects on binding of lysine substitution 
on P9 are less evident with peptides having nonacidic resi-
dues. Indeed this was the case with the register 1:12–20 pep-
tide when having a lysine substitution at P9 but nonetheless 
completely abrogated T cell recognition (Fig. 5 b and Table 
S2). A peptide with the nested register 3:14–22 bound very 
weakly at 5.5 µM.
The nested peptide with register 1 had a considerably 
faster dissociation rate from I-Ag7, with >50% of the bound 
peptide being lost in the first 20 min (Fig. 5 c). In striking 
contrast, the nested 13–21 register 2 showed a very slow rate 
but importantly, we detected a response to the insulin protein 
and to the nested register 2 peptide (Fig. 4 c), both of which 
are absent in NOD mice (Fig. 4 a). Similarly, when we immu-
nized B16A-dKO mice with the nested register 2 peptide, we 
detected a specific T cell response to the B:9–23 peptide, 
insulin protein, and both register 1 and 2 nested peptides 
(Fig. 4 d). The response to register 1:12–20 was unexpected 
and required further examination.
Therefore, we tested a panel of type A hybridomas gener-
ated from B16A-dKO mice. These hybridomas robustly rec-
ognized register 2 and also recognized register 1:12–20 at 
similar levels (Fig. 4 e) or to a weaker extent (Fig. 4 f). We 
therefore  conclude  that  the  dual  reactive  nature  of  these   
T cells explains the unexpected response to register 1 seen after 
immunization  of  these  mice  with  the  nested  register  2   
peptide (Fig. 4 d).
All together, these results confirm that the majority of   
T cells that escape thymic negative selection in NOD mice 
are peptide specific and recognize register 1 of the B:9–23 
peptide. The presence of register 2–reactive T cells in the 
periphery of B16A-dKO mice confirms that the B:13–21 
register plays a critical role in mediating negative selection 
of insulin T cells. It is currently unclear whether many of 
the T  cells  found  in  them  recognize  both  registers  or 
whether they recognize a putative hybrid register of the 
register 1 peptide.
Figure 4.  Immunization of NOD mice gives rise to T cells that recognize register 1 but not register 2 of B:9–23. (a and b) ELISPOT assay of IL-2 
secretion by NOD mice immunized with 10 nmol of B:9–23 or register 1:12–20 nested peptide (TEGVEALYLVCGGGS; a) or insulin or register 2:13–21 
nested peptide (TEGEALYLVCGEGGS; b) in CFA. (c and d) ELISPOT assay of IL-2 secretion by B16A-dKO mice immunized with 10 nmol of B:9–23 (c) or reg-
ister 2:13–21 nested peptide (d) in CFA. (a–d) 106 cells from the draining lymph node were restimulated without antigen (No Ag) or with B:9–23 peptide, 
insulin (INS), register 1, or register 2 nested peptides (all at a dose of 10 µM) in the presence or absence of a specific blocking antibody to I-Ag7 (G7).  
(e and f) Response of insulin-reactive hybridomas B16A-22 (e) and B16A-118 (f) from B16A-dKO mice to B:9–23, nested 12–20 peptide (n-B:12–20), and 
nested 13–21 peptide (n-B:13–21). Error bars indicate SEM. Data are representative of two or more independent experiments (n = 3 mice per group).2380 Register shift dictates diabetogenic T cell fate | Mohan et al.
binding segment. The environment of the lysosomal com-
partment, coupled with the weak binding of register 1 to   
I-Ag7, leads to the generation of pMHC complexes that are 
too unstable to compete and survive their sojourn to the cell 
surface in sufficient quantity to stimulate a T cell response.
The  presentation  of  peptides  bound  in  register  1  was 
found only in the APCs that normally reside within the islets 
of Langerhans (Mohan et al., 2010). Such APCs constitutively 
took up insulin granules, many of which, aside from insulin 
and C-peptide, also contained peptides derived from the in-
sulin B chain. It stands to reason that the constant exposure 
to the secretory granule with preformed insulin B chain 
peptides resulted in a significant number of pMHCs bearing 
the peptide bound in register 1, a situation akin to the reactiv-
ity seen in the culture assays, when APCs are constantly ex-
posed to exogenous synthetic peptides. Whether there are 
of dissociation, and 70% was SDS stable (Fig. 5, d and e). 
In accordance with the weak binding of the nested register 1, 
most  of  the  bound  peptide  dissociated  when  the  pMHC 
complex was run in SDS-PAGE under nonboiling condi-
tions (Fig. 5 e). Addition of H2-DM to the complex of pep-
tide and I-Ag7 increased the fast rate of dissociation of nested 
12–20 to a complete loss after 30 min but had little effect on 
nested 13–21 (Fig. 5 f). In sum, the binding features indicate 
the register 2:13–21 segment with the B21 glutamic acid at 
the P9 MHC anchor residue is much more favorable than 
register 1:12–20 in its interaction with I-Ag7.
The present findings extend the previous report of two 
major sets of insulin-reactive CD4+ T cells (Mohan et al., 
2010), identify their peptide binding segment to MHC, cor-
relate the recognition in in vivo experiments, and present a 
biochemical  explanation  for  their  selection.  Both  sets  of   
T cells were reactive with the B chain of insulin centered on 
a core segment represented by residues 12–21. We show here 
that the 12–21 segment contained two adjacent binding reg-
isters, giving rise to T cells that recognized one or the other. 
More importantly, the register specificity of these T cells cor-
responded to previously identified subsets of type A and B 
insulin–reactive T cells (Mohan et al., 2010), which have 
seminal biological differences.
The minor set of insulin-reactive T cells in vivo, type A, 
recognizes the register 2:13–21 segment of the B:9–23 pep-
tide. These T cells react with the insulin molecule after its 
processing by APCs as well as to the B:9–23 peptide. Such   
T cells are under strong selective pressure in the thymus 
where insulin is expressed (Mohan et al., 2010). Deletion of 
register 2–reactive T cells is not complete, and a limited 
number can be found in the periphery and infiltrated islets of 
NOD mice (Wegmann et al., 1994; Mohan et al., 2010). In 
striking  contrast,  the  majority  of  insulin  T  cells  found  in 
NOD mice, the type B T cells, recognize the 12–20 segment 
of the B:9–23 peptide. These T cells are not activated by any 
source of insulin, explaining their ability to escape thymic 
negative selection. Such T cells are selected by the intraislet 
APCs, spontaneously infiltrate the islets of prediabetic NOD 
mice, and cause diabetes upon transfer (Mohan et al., 2010).
The binding properties of each peptide register plus the 
anatomical  features  of  antigen  presentation  in  the  islet  of 
Langerhans explain the presence and features of the two sets 
of T cells. The binding characteristics of I-Ag7 typically select 
for the presence of peptides bearing one or more acidic resi-
dues at the carboxyl end of the peptide (Corper et al., 2000; 
Latek et al., 2000; Suri et al., 2002, 2005). A minor set of pep-
tides have small residues bound in the P9 pocket (Stratmann 
et al., 2000; Suri et al., 2002, 2005). In the case of the two in-
sulin registers found in the 12–21 segment, register 2 has the 
favorable glutamic acid at P9. This register binds better to   
I-Ag7, has a longer half-life as a pMHC complex, is more sta-
ble in SDS, and is not affected by H2-DM compared with 
register 1, which has a less favorable glycine at P9. The con-
trasting findings of each register are compatible with a sce-
nario in which the processing of insulin selects for the better 
Figure 5.  Binding of register 1:12–20 peptide to I-Ag7 molecules 
is unstable and dissociates rapidly compared with binding of regis-
ter 2:13–21 peptides. (a and b) Response of type A (4F7; a) and type B 
(8F10; b) hybridomas to the nested 12–20 peptide (n-B:12–20), nested 
12–20 K20 peptide (n-B:12–20 K20), nested 13–21 peptide (n-B:13–21), 
and nested 13–21 K21 peptide (n-B:13–21 K21). (c and d) Dissociation 
rate of the 12–20 nested peptide (c) and 13–21 nested peptide (d) from 
soluble I-Ag7 protein. (e) SDS stability of 12–20 nested peptide I-Ag7 com-
plexes and 13–21 nested peptide I-Ag7 complexes. To denature stable 
complexes, samples were boiled before loading as indicated. Molecular 
mass is indicated in kilodaltons. (f) H2-DM editing of soluble peptide  
I-Ag7 complexes. Bars indicate the percentage of remaining peptide  
bound to I-Ag7 after 30 min in the presence of 10-fold molar excess of 
H2-DM. Error bars indicate SEM. Data are representative of 3–10  
independent experiments.JEM Vol. 208, No. 12  2381
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BamHI site to facilitate cloning into the pET-32c vector (EMD) using the 
following primer pairs: NcoI ppINS-1 forward, 5-TCATTACCATGGC-
CCTGTTGGTGCACTTCCTA-3; and BamHI ppINS-1 reverse, 5-CTTA-
GAGGATCCTTAGTTGCAGTAGTTCTCCAG-3; and NcoI ppINS-2 
forward, 5-TCATTACCATGGCCCTGTGGATGCGCTTCCTG-3; and 
BamHI ppINS-2 reverse, 5-CTTAGAGGATCCCTAGTTGCAGTAGT-
TCTCCAG-3. pET-32c-preproinsulin constructs were transformed into 
the  origami  B  (DE3)  pLysS  Escherichia  coli  strain  (EMD).  Bacteria  were 
grown in a shaking incubator (230 rpm) in LB-ampicillin media at 30°C. 
Protein expression was induced when the culture reached an OD600 0.6 
with 0.25 mM IPTG (Roche) for 6 h. Bacteria were isolated by centrifuga-
tion, and after gentle lysis, preproinsulin proteins were isolated from the cyto-
plasmic fraction using Ni-NTA agarose (QIAGEN). Protein was dialyzed 
against PBS, pH 7.5, overnight at 4°C. The isolated protein was then con-
centrated with 10,000 MWCO Centricon columns (Millipore) and treated 
with 1 U/mg thrombin (EMD) to separate expression and solubility tags 
from the preproinsulin proteins. Proteins were dialyzed twice (24 h each) 
against PBS and stored at 4°C.
Cell lines. The T cell hybridomas used in this study were previously de-
scribed (Mohan et al., 2010). To generate C3.G7 cell lines expressing prep-
roinsulin I and II, DNA was amplified from the pCR 2.1 preproinsulin 
constructs using the following primer pairs: NotI ppINS-1 forward, 5-TCAT-
TAGCGGCCGCATGGCCCTGTTGGTGC-3;  and  BamHI  ppINS-1 
reverse (listed in previous section); and NotI ppINS-2 forward, 5-TCAT-
TAGCGGCCGCATGGCCCTGTGGATGCGC-3;  and  BamHI  ppINS-2 
reverse (listed in previous section). Amplified DNA was digested and cloned 
into the pRetroX-IRES-dsRedExpress vector (Takara Bio Inc.). C3.G7–
preproinsulin I and II stable cell lines were generated by retroviral infection 
and sorted multiple times based on dsRed expression for high purity. The 
generation of cell lines with covalently linked pMHC molecules is listed in 
the next section.
Generation of covalently linked pMHC constructs. The I-Ad  chain was 
cloned from NOD splenic cDNA with the following primer pair: NotI G7 
forward,  5-TTATGCGGCCGCATGCCGTGCAGCAGAGCTCT-3; 
and BamHI G7 reverse, 5-TTCAGGATCCTCATAAAGGCCCTGG-
GTGTCT-3 and subsequently cloned into the pQCXIP vector (Takara 
Bio Inc.). The I-Ag7  chain with the B:9–23 peptide covalently linked was 
isolated from a previously described cell line (Mohan et al., 2010) and cloned 
into the pCR 2.1 vector (Invitrogen) with the following primers: NotI G7 
forward,  5-TTATGCGGCCGCATGGCTCTGCAGATCCCCAG-3; 
and BamHI G7 reverse, 5-CATTGGATCCTCACTGCAGGAGCCCT-
GCTGG-3. The B:9–23 peptide was removed by XmaI and SpeI restric-
tion digest. Complementary synthetic oligonucleotides of the desired insulin 
peptide sequences with restriction enzyme sites (XmaI and SpeI) at the 5 
and 3 ends were annealed, digested, and ligated into the I-Ag7  chain con-
struct. The G7 chain with the modified linker (GGSLVPRGSGGGGS) 
and  covalently  bound  insulin  peptide  constructs  were  cloned  in  the 
pRetroX-IRES-dsRedExpress vector (Takara Bio Inc.) using the NotI and 
BamHI restriction sites.
Generation of retrovirus. Phoenix cells (Orbigen) were transfected with 
the pQCXIP I-Ad  plasmid and the VSV envelope plasmid with Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s protocol. After 
48 h, the supernatant was harvested, centrifuged at 3,000 rpm for 10 min to 
remove cellular debris, and then applied to M12.C3 cells with 10 µg/ml 
polybrene (Sigma-Aldrich). Cells were spinfected at 2,500 rpm for 90 min, 
incubated at 37°C overnight, washed, and expanded for another 48 h.   
10 µg/ml puromycin (Sigma-Aldrich) was added for 48 h to select for a stable 
M12.C3.I-Ad  cell line. This line was subsequently infected with viruses 
generated in the same manner containing the G7 peptide constructs. After 
infection with the  chain construct, cells were sorted once for expression of 
dsRed on a high-speed cell sorter. Expression of I-Ag7 was assessed by flow 
cytometry using the AG2.42.7 monoclonal antibody.
other issues with the islet APCs that allow them to select for 
peptides that are bound in register 1 needs to be examined. 
An additional consideration is whether there are unique fea-
tures of the peptides released from  cells that may favor reg-
ister 1 binding.
We were unable to find any evidence for insulin T cells 
recognizing a third register in the B:9–23 segment encom-
passing 14–22 (Stadinski et al., 2010). T cells against the   
14–22 register are unexpected because of the placement of an 
unfavored arginine within the P9 pocket, which results in 
very weak binding to I-Ag7, even weaker than that of register 1 
and 2 segments. The inability to find T cells that recognize 
this register indicates that register 3 is unlikely to play an im-
portant role in diabetes.
In conclusion, biochemical analyses have given several 
explanations  for  the  presentation  of  peptides  from  self-
proteins. Important are the findings emphasized by us, that 
the pMHC complexes presented by APCs in tissues may 
differ from those present in the thymic APC system. We 
called attention to these in the context of the small protein 
HEL where conformational isomers could be distinguished, 
which explained the presence of T cells to one set in HEL 
transgenic mice (Peterson et al., 1999). In the studies of 
spontaneous diabetes in NOD mice, we find selection for 
T cells that recognized a segment in which the register 
shifted to one poorly presented, if at all, in the thymus. 
Previous studies have shown that more than one binding 
register can be selected within a relatively short peptide 
segment,  a  phenomenon  called  register  shifting,  which 
gave rise to nonoverlapping sets of T cells (Scott et al., 
1998; McFarland et al., 1999; Robertson et al., 2000). The 
issue of register shifting to explain the escape of autoimmune   
T cells has also been discussed in autoimmune encephalo-
myelitis  (Anderton  et  al.,  2002;  Seamons  et  al.,  2003; 
Bankovich et al., 2004; Goverman, 2009). The conclusion 
is that self-reactive T cells can potentially become patho-
genic in the target organ where high concentrations of   
antigen and/or differences in intracellular processing re-
quirements lead to the presentation of peptides in alternate 
conformers or, as shown here, in alternate registers to those 
found in the thymus.
MATERIALS AND METHODS
Mice.  NOD  and  NOD.Cg-Tg(Ins2*Y16A)1Ell  Ins1tm1Jja  Ins2tm1Jja/GseJ 
(B16:A-dKO) mice were obtained from the Jackson Laboratory and main-
tained in specific pathogen–free conditions. All animal experiments were   
approved by the Animal Study Committee of Washington University in   
St. Louis.
Expression and isolation of mouse preproinsulin proteins. Mouse 
preproinsulin I and II cDNAs were generated from RNA isolated from 
NOD pancreatic islet cells. These cDNAs were cloned into the pCR 2.1 
TOPO vector (Invitrogen) using the following primer pairs: preproinsulin I 
forward primer, 5-ATGGCCCTGTTGGTGCACTTCCTA-3; and re-
verse primer, 5-TTAGTTGCAGTAGTTCTCCAG-3; and preproinsulin II 
forward  primer,  5-ATGGCCCTGTGGATGCGCTTCCTG-3;  and 
reverse primer, 5-CTAGTTGCAGTAGTTCTCCAG-3. The prepro-
insulin DNA was subsequently amplified to contain a 5 NcoI site and 3 2382 Register shift dictates diabetogenic T cell fate | Mohan et al.
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Antigen presentation assays. T cell assays were performed in triplicate in 
96-well flat-bottom tissue culture plates. T cell hybridomas (5 × 104 per 
well) were cultured with 5 × 104 C3.G7 cells in the presence of the indicated 
doses of antigen. All peptides used in this study were synthesized in the labo-
ratory using standard protocols. After incubation for 18 h, the culture super-
natant from each well was assayed for IL-2 production by a standard bioassay 
using the IL-2–dependent cell line CTLL-2.
Immunizations and ELISPOT analysis. Immunizations and ELISPOT 
were performed as previously described (Mohan et al., 2010). In brief, mice 
were immunized in the hind foot pad with either 10 nmol insulin (Sigma-
Aldrich) or synthetic peptide emulsified in CFA (Difco). On day 7, the 
draining popliteal lymph nodes were isolated and dissociated into a single cell 
suspension and used in an IL-2 ELISPOT assay according to the manufac-
turer’s  protocol  (BD).  Blocking  of  I-Ag7  was  performed  by  adding  the 
AG2.42.7 antibody (2 µg/well) 30 min before adding antigen.
Biochemical analysis. Biochemical analysis was performed using soluble 
I-Ag7 and H2-DM molecules purified from baculoviruses, the same con-
structs used in previous studies (Pu et al., 2004; Levisetti et al., 2007). Bind-
ings  were  performed,  as  detailed  previously  (Levisetti  et  al.,  2007),  by 
competition assays of unlabeled peptides to standard  125I-labeled peptide. 
The labeled peptide (GKKVATTVHAGYG) was used at concentrations 
that bound 25% of input; the concentration of unlabeled peptide that in-
hibits the binding by 50% was determined. All assays were performed at least 
three times. For experiments measuring the rate of dissociation, radioactive 
peptide bearing the nested register 1:12–20 or register 2:13–21 sequence was 
bound to I-Ag7 overnight at pH 5.5, after which a 1,000-fold excess of cold 
peptide was added, and the amounts of labeled peptide were then deter-
mined in the isolated complex. In some experiments, H2-DM at a 10-fold 
excess molar ratio was added. Peptides used in the bindings assays shown in 
Table S2 contained three constant residues at the N terminus (TEG) and 
three at the C terminus (GGS) and the core sequence indicated in the table. 
For dissociation assays, the peptides were made with an added tyrosine at the 
N terminus and changing the tyrosine at B16 to phenylalanine (YEGVEAL-
FLCGGGS and YEGEALFLVGEGGS). The peptides were labeled with 125I 
by the chloramine T method.
Online supplemental material. Table S1 lists the sequences of the cova-
lent pMHC molecules and the reactivity of T cells examined. Table S2 lists 
the sequences of the synthetic peptides, their binding affinity to I-Ag7, and 
the reactivity of T cells examined. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20111502/DC1.
We thank Stephen Horvath and Paul Allen for help with peptide synthesis and 
members of the Unanue laboratory for comments and advice.
This research was supported by National Institutes of Health grants 
AI024742, DKo58177, and P60DK20579, by the Juvenile Diabetes Research 
Foundation grant JDRF 1-2007-731, and by grants from the Kilo Diabetes and 
Vascular Research Foundation.
The authors have no conflicting financial interests.
Submitted: 20 July 2011
Accepted: 12 October 2011
REFERENCES
Anderton, S.M. 2004. Post-translational modifications of self antigens: im-
plications for autoimmunity. Curr. Opin. Immunol. 16:753–758. http://
dx.doi.org/10.1016/j.coi.2004.09.001
Anderton, S.M., N.J. Viner, P. Matharu, P.A. Lowrey, and D.C. Wraith. 
2002. Influence of a dominant cryptic epitope on autoimmune T cell 
tolerance. Nat. Immunol. 3:175–181. http://dx.doi.org/10.1038/ni756
Bankovich, A.J., A.T. Girvin, A.K. Moesta, and K.C. Garcia. 2004. Peptide 
register  shifting  within  the  MHC  groove:  theory  becomes  reality. 
Mol.  Immunol.  40:1033–1039.  http://dx.doi.org/10.1016/j.molimm 
.2003.11.016JEM Vol. 208, No. 12  2383
Brief Definitive Report
Pu, Z., S.B. Lovitch, E.K. Bikoff, and E.R. Unanue. 2004. T cells dis-
tinguish MHC-peptide complexes formed in separate vesicles and ed-
ited  by  H2-DM.  Immunity.  20:467–476.  http://dx.doi.org/10.1016/ 
S1074-7613(04)00073-1
Robertson, J.M., P.E. Jensen, and B.D. Evavold. 2000. DO11.10 and OT-II 
T cells recognize a C-terminal ovalbumin 323-339 epitope. J. Immunol. 
164:4706–4712.
Scott, C.A., P.A. Peterson, L. Teyton, and I.A. Wilson. 1998. Crystal struc-
tures of two I-Ad-peptide complexes reveal that high affinity can be 
achieved without large anchor residues. Immunity. 8:319–329. http://
dx.doi.org/10.1016/S1074-7613(00)80537-3
Seamons,  A.,  J.  Sutton,  D.  Bai,  E.  Baird,  N.  Bonn,  B.F.  Kafsack,  J. 
Shabanowitz, D.F. Hunt, C. Beeson, and J. Goverman. 2003. Com-
petition between two MHC binding registers in a single peptide pro-
cessed from myelin basic protein influences tolerance and susceptibility 
to autoimmunity. J. Exp. Med. 197:1391–1397. http://dx.doi.org/10 
.1084/jem.20022226
Stadinski, B.D., L. Zhang, F. Crawford, P. Marrack, G.S. Eisenbarth, and 
J.W. Kappler. 2010. Diabetogenic T cells recognize insulin bound to 
IAg7 in an unexpected, weakly binding register. Proc. Natl. Acad. Sci. 
USA. 107:10978–10983. http://dx.doi.org/10.1073/pnas.1006545107
Stratmann, T., V. Apostolopoulos, V. Mallet-Designe, A.L. Corper, C.A. 
Scott, I.A. Wilson, A.S. Kang, and L. Teyton. 2000. The I-Ag7 MHC 
class II molecule linked to murine diabetes is a promiscuous peptide 
binder. J. Immunol. 165:3214–3225.
Suri, A., I. Vidavsky, K. van der Drift, O. Kanagawa, M.L. Gross, and E.R. 
Unanue. 2002. In APCs, the autologous peptides selected by the diabe-
togenic I-Ag7 molecule are unique and determined by the amino acid 
changes in the P9 pocket. J. Immunol. 168:1235–1243.
Suri, A., J.J. Walters, M.L. Gross, and E.R. Unanue. 2005. Natural pep-
tides selected by diabetogenic DQ8 and murine I-A(g7) molecules show 
common sequence specificity. J. Clin. Invest. 115:2268–2276. http://
dx.doi.org/10.1172/JCI25350
Wegmann, D.R., R.G. Gill, M. Norbury-Glaser, N. Schloot, and D. 
Daniel. 1994. Analysis of the spontaneous T cell response to insulin in 
NOD mice. J. Autoimmun. 7:833–843. http://dx.doi.org/10.1006/ 
jaut.1994.1066
Yu, B., L. Gauthier, D.H. Hausmann, and K.W. Wucherpfennig. 2000. 
Binding of conserved islet peptides by human and murine MHC 
class  II  molecules  associated  with  susceptibility  to  type  I  diabetes. 
Eur.  J.  Immunol.  30:2497–2506.  http://dx.doi.org/10.1002/1521-
4141(200009)30:9<2497::AID-IMMU2497>3.0.CO;2-J